| By PR Newswire | Article Rating: |
|
| January 3, 2013 07:30 AM EST | Reads: |
130 |
CRANBURY, N.J., Jan. 3, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today it has received net proceeds of approximately $1.75 million of non-dilutive funding through the New Jersey Economic Development Authority's tax credit transfer program. Palatin Technologies sold both New Jersey net operating losses and research and development tax credits to unrelated corporations.
Last year, Palatin Technologies received approximately $1.1 million under this program.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.
SOURCE Palatin Technologies, Inc.
Published January 3, 2013 Reads 130
Copyright © 2013 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

